Liquidia (LQDA) Interest & Investment Income (2020 - 2026)
Liquidia's (LQDA) quarterly Interest & Investment Income came in at $1.8 million in Q1 2026, up 2.55% year-on-year from $1.7 million in Q1 2025, and up 6.3% quarter-over-quarter from $1.7 million in Q4 2025.
Liquidia (LQDA) Interest & Investment Income (2020 - 2026) Analysis & Trends
Liquidia's Interest & Investment Income history runs 7 years deep, the most recent figure standing at $1.8 million for Q1 2026.
- On a quarterly basis, Interest & Investment Income rose 2.55% year-over-year to $1.8 million in Q1 2026; TTM through Mar 2026 was $6.7 million, a 11.12% decrease from a year earlier, with the FY2025 full-year figure at $6.6 million, down 13.46% from the prior year.
- Interest & Investment Income improved to $1.8 million in Q1 2026 per LQDA's latest filing, from $1.7 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $2.1 million in Q4 2024 and bottomed at $4000.0 in Q1 2022.
- The 5-year median for Interest & Investment Income is $1.6 million (2025), against an average of $1.2 million.
- Across the five-year window, Interest & Investment Income plunged 80.95% in 2022 and jumped 22950.0% in 2023, its largest moves.
- Year by year, Interest & Investment Income stood at $662000.0 in 2022, then soared by 43.2% to $948000.0 in 2023, then surged by 121.94% to $2.1 million in 2024, then decreased by 20.77% to $1.7 million in 2025, then increased by 6.3% to $1.8 million in 2026.
- Per Business Quant, the three latest LQDA Interest & Investment Income figures stand at $1.8 million (Q1 2026), $1.7 million (Q4 2025), and $1.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 32.85 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 41.80 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 28.10 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Liquidia | 7.47 Bn | 7.25 Bn | 121.79 Mn | 1.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.77 Mn |
| Dec 31, 2025 | 1.67 Mn |
| Sep 30, 2025 | 1.65 Mn |
| Jun 30, 2025 | 1.58 Mn |
| Mar 31, 2025 | 1.73 Mn |
| Dec 31, 2024 | 2.10 Mn |
| Sep 30, 2024 | 1.82 Mn |
| Jun 30, 2024 | 1.86 Mn |
| Mar 31, 2024 | 1.88 Mn |
| Dec 31, 2023 | 948,000.00 |
| Sep 30, 2023 | 862,000.00 |
| Jun 30, 2023 | 734,000.00 |
| Mar 31, 2023 | 922,000.00 |
| Dec 31, 2022 | 662,000.00 |
| Sep 30, 2022 | 359,000.00 |
| Jun 30, 2022 | 65,000.00 |
| Mar 31, 2022 | 4,000.00 |
| Dec 31, 2021 | 3,000.00 |
| Sep 30, 2021 | 4,000.00 |
| Jun 30, 2021 | 5,000.00 |